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Abstract 
Background: New anti-malarial therapeutics are required to counter the threat of increasing drug resistance. Malaria 
volunteer infection studies (VIS), particularly the induced blood stage malaria (IBSM) model, play a key role in acceler-
ating anti-malarial drug development. Supply of the reference 3D7-V2 Plasmodium falciparum malaria cell bank (MCB) 
is limited. This study aimed to develop a new MCB, and compare the safety and infectivity of this MCB with the exist-
ing 3D7-V2 MCB, in a VIS. A second bank (3D7-V1) developed in 1995 was also evaluated.
Methods: The 3D7-V2 MCB was expanded in vitro using a bioreactor to produce a new MCB designated 
3D7-MBE-008. This bank and 3D7-V1 were then evaluated using the IBSM model, where healthy participants were 
intravenously inoculated with blood-stage parasites. Participants were treated with artemether-lumefantrine when 
parasitaemia or clinical thresholds were reached. Safety, infectivity and parasite growth and clearance were evaluated.
Results: The in vitro expansion of 3D7-V2 produced 200 vials of the 3D7-MBE-008 MCB, with a parasitaemia of 
4.3%. This compares to 0.1% in the existing 3D7-V2 MCB, and < 0.01% in the 3D7-V1 MCB. All four participants (two 
per MCB) developed detectable P. falciparum infection after inoculation with approximately 2800 parasites. For the 
3D7-MBE-008 MCB, the parasite multiplication rate of 48 h  (PMR48) using non-linear mixed effects modelling was 34.6 
(95% CI 18.5–64.6), similar to the parental 3D7-V2 line; parasitaemia in both participants exceeded 10,000/mL by day 
8. Growth of the 3D7-V1 was slower  (PMR48 of 11.5 [95% CI 8.5–15.6]), with parasitaemia exceeding 10,000 parasites/
mL on days 10 and 8.5. Rapid parasite clearance followed artemether-lumefantrine treatment in all four participants, 
with clearance half-lives of 4.01 and 4.06 (weighted mean 4.04 [95% CI 3.61–4.57]) hours for 3D7-MBE-008 and 4.11 
and 4.52 (weighted mean 4.31 [95% CI 4.16–4.47]) hours for 3D7-V1. A total of 59 adverse events occurred; most were 
of mild severity with three being severe in the 3D7-MBE-008 study.
Conclusion: The safety, growth and clearance profiles of the expanded 3D7-MBE-008 MCB closely resemble that of 
its parent, indicating its suitability for future studies. Trial Registration: Australian New Zealand Clinical Trials registry 
numbers: P3487 (3D7-V1): ACTRN12619001085167. P3491 (3D7-MBE-008): ACTRN12619001079134
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Background
Malaria continues to cause major morbidity and mor-
tality worldwide, with current control measures being 
threatened by the spread of artemisinin-resistance in 
the Greater Mekong Subregion [1–3]. New anti-malar-
ial drugs and vaccines are, therefore, urgently required. 
The current anti-malarial drug pipeline has been accel-
erated by the use of human volunteer infection stud-
ies (VIS) [4–8], particularly the induced blood-stage 
malaria model (IBSM) [5, 6]. In these studies, healthy, 
malaria-naïve participants are inoculated with Plas-
modium-infected erythrocytes, enabling the assess-
ment of the blood stage schizont activity of antimalarial 
drug candidates [5, 6, 9–11]. As of March 2020, 401 
volunteers have been inoculated with the Plasmodium 
falciparum 3D7 clone, most at QIMR Berghofer in Bris-
bane, Australia (n = 335), but some at sites in the Neth-
erlands and UK (n = 66) [6, 12–16].
The current QIMR Berghofer malaria cell bank 
(MCB) used to inoculate volunteers with P. falciparum, 
termed 3D7-V2, was produced in 1995 [17–19]. At that 
time, two volunteers were experimentally infected by 
mosquito bite with Plasmodium falciparum 3D7, and 
500  mL of blood was collected from each volunteer 
six hours following the onset of fever [19]. Although 
two MCBs were produced (3D7-V1 and 3D7-V2), the 
higher parasitaemia in the 3D7-V2 bank (0.1% com-
pared to < 0.01% of erythrocytes parasitized, respec-
tively) has led to this bank being utilized in subsequent 
malaria VIS. The 3D7-V1 has been utilized only once, 
for re-inoculation into the original donor [19].
Stocks of the P. falciparum 3D7-V2 MCB are lim-
ited, therefore, further MCBs are required to ensure 
an ongoing supply of this valuable resource. The devel-
opment of further banks can be undertaken by col-
lection of samples from malaria-infected patients or 
experimentally infected volunteers [17]. An alternative 
approach is the in  vitro manufacture of banks using a 
bioreactor, such as the Wave ™ 25 bioreactor system 
[17]. This method has been used previously to produce 
and test in vivo two cell banks, a genetically modified P. 
falciparum blood stage-cell bank [17], and an artemini-
sin-resistant P. falciparum cell bank [20]. This proved 
to be a cost-efficient method for the production of a 
MCB for use in IBSM studies [17, 21]. This method also 
allows for blood group selection of the MCB.
The development of a new MCB, 3D7-MBE-008 
(MBE-008), using this biomanufacture process, and 
the clinical evaluation of this MCB is reported. Safety, 
infectivity and parasite growth and clearance of the 
3D7-MBE-008 and the previous 3D7-V1 were com-
pared to the existing data on the 3D7-V2 bank.
Methods
Development of 3D7‑MBE‑008 Master Cell Bank
The 3D7-MBE-008 MCB was manufactured in accord-
ance with Good Manufacturing Practice standards [22] 
in 2015 using the previously described method [17]. In 
brief, a single vial of the 3D7-V2 MCB was thawed and 
expanded using the bioreactor. Erythrocytes used in the 
production of the MCB were from a single blood group O 
Rh (D) negative donor, provided by Lifeblood (formerly 
Australian Red Cross Blood Service). The donor was 
screened in accordance with TGA regulatory require-
ments for donation of blood for transfusion. Pooled, heat 
inactivated serum collected from donors by Key Biolog-
ics (Memphis, Tennessee, U.S.) used in the manufac-
turing process was also extensively screened. The final 
3D7-MBE-008 culture was cryopreserved with Glycero-
lyte 57 in 1:2.2 ratio, and aliquoted to produce 200 1 mL 
cryovials, which were stored between −140 and −196 °C 
in secure, monitored vapour phase liquid nitrogen tanks 
at Q-Gen Cell Therapeutics, Brisbane, Australia.
Laboratory testing of the Master Cell Banks
The percentage of parasitized erythrocytes and the per-
centage of ring-stage parasites were determined via thin 
film microscopy for 3D7-MBE-008 and thick film micros-
copy for 3D7-V1. Testing for microbial contamination 
was performed in line with the British Pharmacopoeia 
Appendix XVI E- microbial contamination of cellular 
products [23].
Parasite viability of 3D7-MBE-008 was determined 
using flow cytometry as previously described [20] at the 
time of manufacture and then in an ongoing stability and 
sterility program, with testing every 12 months. The via-
bility of the parasites in the 3D7-V1 bank was determined 
at the time of manufacture by limiting dilution assay fol-
lowed by PCR as previously described [19].
For confirmation of parasite identity, the DNA 
sequence of three widely used hypervariable genes (P. 
falciparum merozoite surface protein-1 [Pf MSP-1], Pf 
MSP-2 and Pf glutate-rich protein [Pf GLURP]) from 
3D7-MBE-008 were compared to 3D7-V2. In vitro drug 
sensitivity testing to nine antimalarials was also under-
taken as previously described [19].
Inoculum preparation
The viability of ring stage parasites in the MBE-008 MCB 
was assessed by flow cytometry as previously described 
[20], to identify the dilution required to achieve an inocu-
lum dose similar to 3D7-V2 MCB. To prepare the inocu-
lum, one or more vials of the MCB were thawed, with the 
resulting red cell pellet washed and resuspended in 0.9% 
sodium chloride. The washed cell suspension was then 
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diluted with 0.9% sodium chloride to achieve the target 
number of viable ring-stage parasites in each 2 ml inocu-
lum, taking into account the characteristics of each MCB 
including the percentage of parasitized erythrocytes, the 
percentage of ring-stage erythrocytes, and parasite via-
bility. The number of parasites in the final inoculum was 
verified by 18S quantitative PCR targeting the P. falcipa-
rum 18S rRNA gene (qPCR) [24] with results available 
after inoculation.
Clinical study design
Two concurrent IBSM studies were conducted, one with 
the 3D7-V1 MCB and the other with 3D7-MBE-008. Each 
study consisted of two single-participant cohorts, with a 
5-week period between cohorts. The primary objective 
of both studies was safety. Secondary objectives included 
infectivity, parasite growth and clearance, the latter fol-
lowing administration of artemether-lumefantrine.
The studies were conducted at Q-Pharm Pty Ltd, 
Brisbane, Australia. Ethical approval was given by 
QIMR Berghofer Human Research Ethics Commit-
tee (HREC), and by Lifeblood HREC for P. falciparum 
3D7-MBE-008. All participants gave written informed 
consent before enrolment. Both studies were registered 
with the Australian New Zealand Clinical Trials registry; 
3D7-V1 (ACTRN12619001085167) and 3D7-MBE-008 
(ACTRN12619001079134).
Participants
Participants were eligible if they were aged 18–55 years, 
healthy and malaria-naïve (see Additional file 1: Appen-
dix for inclusion and exclusion criteria). For the 3D7-V1 
study, only males who were blood group Rh(D) positive 
were eligible, due to the fact that the 3D7-V1 MCB donor 
was Rh(D) positive.
Procedures
All participants were inoculated with approximately 2800 
viable infected erythrocytes on Day 0. Parasitaemia was 
monitored by 18S qPCR daily [24] from Day 4 until para-
sites were detected, then twice daily until artemether-
lumefantrine (20  mg artemether/ 120  mg lumefantrine; 
Novartis Pharmaceuticals Pty Ltd) was given, and then 
at specified timepoints post treatment until qPCR was 
negative (Additional file 1: Table S1). Figure 1a illustrates 
the study design for 3D7-V1 MCB and Fig. 1b illustrates 
the study design for 3D7-MBE-008 MCB. The protocol 
specified that a curative course of artemether-lumefan-
trine, consisting of 6 doses of 4 tablets over a 60-h period, 
would be given when the participants’ parasitaemia 
exceeded 10,000 parasites/mL, or the participants’ malar-
ial clinical score was ≥ 6 (see Additional file 1 for calcu-
lation of malaria clinical score). However, due to slower 
than expected parasite growth in the first subject inocu-
lated with 3D7-V1, and lack of any clinical symptoms in 
the participant at a parasite count of 10,000 parasites/
mL, the 3D7-V1 protocol was amended to change the 
parasite treatment threshold to 100,000 parasites/mL.
Safety assessments
Safety was evaluated by recording all adverse events as 
well as any abnormal laboratory results. Investigations 
were performed at the timepoints specified in Additional 
file 1: Table S1. During every outpatient visit and during 
confinement, a malaria clinical score for each participant 
was generated. A graded assessment of symptoms and 
laboratory results was used (see Additional file 1).
Parasite growth and clearance
The parasite multiplication rate of 48 h  (PMR48) for each 
MCB was calculated by applying the pre-treatment qPCR 
data to a sine-wave growth model, estimated using a 
non-linear mixed effects model in R Statistical package 
3.6.1, as previously reported [25]. The  PMR48 for each 
MCB was then presented as an estimate with a 95% CI. 
To determine if there were any significant differences 
between the growth model parameter estimates from 
the new MCBs and the previously used 3D7-V2 MCB, 
an omnibus test for between-group differences was used 
[26]. The sine- wave growth model estimated using a non-
linear regression model was also used to retrospectively 
calculate the parasite growth characteristics of 3D7-V1 in 
the initial volunteer re-infected with his isolate (3D7-V1) 
in 1995. The parasite clearance profiles post artemether-
lumefantrine treatment for each participant were esti-
mated from the slope of best fit of the parasite clearance 
rate and transformed to estimate the parasite reduction 
ratio (PRR) per 48 h in the logarithmic-scale  (log10PRR48) 
and the parasite clearance half-life as previously reported 
[27], using R Statistical package 3.6.1. Parasite clearance 
parameters for each bank are summarized as a weighted 
mean and corresponding 95% CI estimated using the 
inverse variance method as detailed in [27].
Results
MCB characteristics
The blood used for the biomanufacture of 3D7-MBE-008 
tested negative for microbial contamination and for 
serologic evidence of infective agents. Manufacture was 
completed in November 2015 and produced 200 vials. 
The analysis of the three genetic markers (Pf msp-1, Pf 
msp-2 and Pf glurp) showed that no changes had taken 
place between the starting 3D7-V2 MCB and resulting 
3D7-MBE-008 MCB, ruling out high level genetic change 
during the biomanufacturing process. The in  vitro drug 
sensitivity of the 3D7-MBE-008 MCB showed the same 
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drug sensitivity profile as the established parental line to 
nine antimalarials (sensitive to amodiaquine, atovaquone, 
artemisinin, chloroquine, lumefantrine, piperaquine, 
pyronaridine and quinine; resistant to mefloquine). The 
parasite concentration of 3D7-MBE-008 MCB was 4.3%, 
with 96% of parasites in ring-stage.
Viability of the 3D7-MBE-008 MCB at 12, 24 and 
36 months (prior to use) was 83%, 71% and 63%, respec-
tively. Microbial contamination testing at these time 
points was negative. The parasitaemia of 3D7-V1 at the 
time of collection was 0.01%. The viability as measured 
by limit dilution and PCR [19] at the time of manufacture 
was approximately 34%.
Study participants
The studies were conducted between August 2019 and 
December 2019.Two participants were enrolled into each 
study. A total of 22 potential volunteers were screened 
for the 3D7-MBE-008 study and 19 for 3D7-V1. All four 
inoculated participants completed the study and are 
included in the safety and parasite profile analysis. The 
participants for the 3D7-MBE-008 study were a 32-year-
old white male and a 31-year-old white non-pregnant 
female. The participants for the 3D7-V1 study were both 
19-year-old white males.
Inoculation and parasite growth
In the 3D7-MBE-008 study, the number of parasites 
in each of the inocula, determined retrospectively by 
18S qPCR, was 18,700 and 23,100. Both participants 
had parasitaemia detectable by 18S qPCR on Day 4 and 
reached threshold parasitaemia (> 10,000 parasites/
mL) on Day 8, when artemether-lumefantrine was com-
menced. The parasite counts prior to treatment were 
141,416 parasites/mL and 480,871 parasites/mL, with 
peak parasitaemia reached for both subjects at 2 h post 
administration of artemether-lumefantrine (239,278 par-
asites/mL and 563,886 parasites/mL) (Fig.  2). Using the 
non-linear mixed effects model estimates, the estimated 
 PMR48 was 34.6 (95% CI 18.5–64.6) (Table 1), similar to 
Fig. 1 Study Design. In both studies, participants were inoculated with approximately 2800 infected erythrocytes on Day 0, followed by 
artemether-lumefantrine treatment when threshold parasitaemia was reached (> 10,000 parasites/mL). The participants were confined for 3 days, 
during which they were treated with artemether-lumefantrine. The last study visit occurred on Day 90 ± 2. For the 3D7-V1 study, the confinement 
period occurred between Day 10–13 (Panel a). For the 3D7-MBE-008 study, the confinement period commenced on Day 8 (Panel b)
Page 5 of 9Woolley et al. Malar J           (2021) 20:93  
that reported in a large meta-analysis of the growth rate 
of 3D7-V2 in previous VIS, which is 31.9 (95% CI 28.7–
35.4) [25]. There were no significant differences between 
the growth parameters of 3D7-MBE-008 (n = 2) and 3D7-
V2 (n = 177) (see Additional file 1: Table S2).
In the 3D7-V1 study, the number of parasites in each 
inocula, determined retrospectively by qPCR, was 
approximately 3050 and 2694 respectively. Participant 
one developed detectable parasitaemia on day 5, whereas 
the second participant had detectable parasitaemia on 
day 4. The parasitaemia in both participants increased 
more slowly than those inoculated with 3D7-MBE-008, 
despite them being derived from the same parental 3D7 
clone; on day 8, when treatment was expected to be 
required, the parasitaemias of the two participants were 
only 1776 parasites/mL and 2982 parasites/mL, respec-
tively, with malaria clinical scores of zero in both par-
ticipants. An urgent protocol amendment was approved 
by the HREC to allow treatment to be administered at 
a parasite threshold of > 100,000 parasites/mL, and the 
two participants were, therefore, treated on days 12 (first 
participant) and day 11 (second participant). For the first 
participant the pre-treatment parasite count was 17,699 
parasites/mL, and the peak parasite count (day 11) was 
64,786 parasites/mL. For the second participant, the pre-
treatment parasite count was 340,789 parasites/mL, and 
the peak parasite count (occurring 4 h post artemether-
lumefantrine) was 742,813 parasites/mL. The estimated 
 PMR48 for 3D7-V1 was 11.5 (95% CI 8.5–15.6) (Table 1). 
The primary parasitaemia data from the original 3D7-
V1 subject that had been calculated using a different 
method [19] was retrieved. Using these data in the sine 
wave growth model, the  PMR48 for 3D7-V1 in the ini-
tial volunteer re-infected in 1995 was 6.4 (95% CI 4.6–
8.8) (Table  1). Due to the heterogeneity in the method 
of calculation of parasitaemia between these studies, a 
combined analysis was not performed. The tests of het-
erogeneity of the individual growth parameters of the 
3D7-V1 and existing 3D7-V2 MCB showed a significant 
difference between the parasite growth rate (p < 0.001) 












































Fig. 2 Parasite growth and clearance after artemether-lumefantrine 
(AL) treatment Parasitaemia from Day 4 to Day 60 for the 
3D7-MBE-008 study (Panel a). Parasitaemia from Day 4 to Day 60 for 
the 3D7-V1 study (Panel b). The vertical dashed lines represent the 
administration of artemether-lumefantrine treatment
Table 1 Summary of parasite growth and clearance characteristics
n, number of participants; CI, 95% confidence intervals; PMR, parasite multiplication rate; PRR, parasite reduction ratio. Growth parameter estimates are calculated 
from a non-linear mixed effects model. Clearance parameter estimates  (PRR48,  log10  PRR48 and parasite clearance half-life) are calculated from a weighted mean of 
individual clearance parameters estimates
Parameter 3D7‑V1 (n = 2) Estimate 
(95% CI)
3D7‑MBE‑008 (n = 2) 
Estimate (95% CI)
3D7‑V1 1995 (n = 1) 
Estimate (95% CI)
3D7‑V2 (n = 177) 
Estimate (95% CI) 
[25]
PMR48 11.5 (8.5–15.6) 34.6 (18.5–64.6) 6.4 (4.6–8.8) 31.9 (28.7–35.4)
Lifecycle (hours) 36.5 (35.0–38.0) 38.8 (36.7–40.8) 42.5 (39.2–45.8) 38.8 (38.3–39.2)
Growth rate  (log10 parasites/day) 0.52 (0.30–0.74) 0.80 (0.54 –1.10) 0.35 (0.13–0.58) 0.63 (0.59–0.66)
PRR48 2254 (1705–2979) 3806 (1446–10018) _ _
log10  PRR48 3.35 (3.23–3.47) 3.58 (3.16–4.00) _ _
Parasite clearance half life 4.31 (4.16–4.47) 4.04 (3.61–4.57) _ _
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and parasite lifecycle (p ≤ 0.001) (Additional file  1: 
Table S3).
Parasite clearance
Parasitaemia cleared in all four participants following 
the administration of artemether-lumefantrine. In the 
3D7-MBE-008 study, the parasite clearance half-lives in 
the two participants were 4.01 and 4.06 (weighted mean 
4.04, 95% CI 3.61–4.57) hours, and the  log10PRR48′s were 
3.60 and 3.56 (weighted mean 3.58, 95% CI 3.16–4.00) h. 
In the 3D7-V1 study, the parasite clearance half-lives in 
the two participants were 4.11 and 4.52 (weighted mean 
4.31, 95% CI 4.16–4.47) hours and the  log10PRR48′s were 
3.52 and 3.20 (weighted mean 3.35, 95% CI 3.23–3.47) h 
in the 3D7- V1 study (Table 1).
Adverse events
There were 35 reported adverse events in the 
3D7-MBE-008 study and 24 in the 3D7-V1 study (see 
Table 2). In the 3D7-MBE-008 study the majority of the 
adverse events were mild or moderate (32/35, 91.4%) 
and attributable to early malaria (25/35, 71.4%); three 
were graded as severe (two episodes of lymphope-
nia; see below) and one of raised alanine transaminase 
[ALT]; see below). In the 3D7-V1 study, the major-
ity of adverse events were mild (14/24, 58.3%), with the 
remainder being moderate; nearly all were attributable 
to early malaria (23/24, 95.8%). There were no serious 
adverse events reported in either study. The most com-
mon adverse events reported across both studies were 
chills (n = 6), headaches (n = 6) and myalgia (n = 7). One 
of the participants in the 3D7-MBE-008 study had a max-
imum malaria clinical score of 9 (8  h post artemether/
lumefantrine) (see Table  S4). One of the participants 
in the 3D7-V1 study had a maximum score of 8 (36  h 
post artemether/lumefantrine) (see Additional file  1: 
Table S5).
One participant in each study developed a raised ALT. 
One participant in the 3D7-MBE-008 study had a peak 
ALT on Day 11 of 191 U/L (4.8 × ULN [upper limit of 
normal]) which normalized by Day 59. The peak aspar-
tate aminotransferase (AST), also on Day 11, was 122 
U/L (3.1 × ULN) and it normalized on Day 15. The bili-
rubin was normal. In the 3D7-V1 study, one participant 
had a peak ALT on Day 14 of 128 U/L (3.2 × ULN) which 
normalized by Day 27. The AST and bilirubin were not 
significantly raised.
Three participants developed transient falls in white 
cell counts that were classified as moderate or severe: 
lymphopenia (3D7-V1, nadir of 0.42 × 109/L, lower 
limit of normal [LLN] = 1.0 × 109/L]; 3D7-MBE-008, 
nadir of 0.34 × 109/L and 0.39 × 109/L); neutropenia 
(3D7-MBE-008 n = 1, 1.35 × 109/L, LLN = 1.5 × 109/L). 
These transient reductions were attributed to malaria.
Discussion
Here we report the manufacture and evaluation of a new 
P. falciparum MCB that can be utilized in future IBSM 
studies. In  vivo testing of 3D7-MBE-008 MCB, and the 
previously manufactured 3D7-V1 MCB, indicated that 
they were well tolerated in healthy, malaria-naïve par-
ticipants. The  PMR48 for the 3D7-MBE-008 MCB was 
comparable to the existing 3D7-V2 MCB. In contrast, the 
3D7-V1 MCB had a slower  PMR48, with the parasitaemia 
of one participant not exceeding 10,000 parasites/mL 
until Day 10, two days later than generally occurs with 
3D7-V2.
Table 2 Adverse events reported during the studies
N, total number of participants in each cohort; n, number of participants 
reporting the adverse event; M, number of occurrences of adverse events. 
Adverse events were coded to System Organ Class and Preferred Term using 
MedDRA Version 20.1
Adverse event 3D7‑V1 (N = 2) 
n (M)
3D7‑MBE‑008 
(N = 2) n (M)
Systemic
 Arthralgia 2 (2) 0 (0)
 Chills 2 (3) 2 (3)
 Decreased appetite 1 (1) 1 (1)
 Fatigue 1 (2) 0 (0)
 Feeling hot 1 (1) 1 (1)
 Headache 2 (3) 2 (3)
 Lethargy 0 (0) 1 (1)
 Malaise 1 (1) 0 (0)
 Myalgia 2 (3) 2 (4)
 Pyrexia 2 (2) 2 (3)
 Sweating 2 (2) 1 (3)
 Tachycardia 1 (1) 1 (2)
Laboratory abnormalities
 ALT increased 1 (1) 1 (1)
 AST increased 0 (0) 1 (1)
 Lymphocyte count decreased 1 (1) 2 (1)
 Neutrophil count decreased 0 (0) 1 (1)
Gastrointestinal
 Abdominal pain 0 (0) 2 (2)
 Constipation 0 (0) 1 (1)
 Diarrhoea 0 (0) 2 (2)
Other
 Back pain 0 (0) 1 (1)
 Erythema (from tape) 0 (0) 1 (1)
 Pain (venepuncture site) 0 (0) 1 (1)
 Ulcer (lip) 0 (0) 1 (1)
 Upper respiratory tract infection 1 (1) 0 (0)
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The parasite growth parameters of the 3D7-V1 in this 
study were similar to those obtained when the same non-
linear growth model was applied to the data from the ini-
tial donor re-infected with 3D7-V1 in 1995 [19, 25]. The 
estimated  PMR48 in the two subjects in this trial was 11.5 
(95% CI 8.5–15.6) compared to 6.4 (95% CI 4.6–8.8) in 
the original volunteer inoculated in 1995. This suggests 
that loss of viability of the parasites after cryopreserva-
tion for over twenty years was not the reason for the 
slower PMR.
One possible explanation for slower than expected 
growth of the 3D7-V1 MCB was the lower number of 
infected red cells in this inoculum. Because the parasite 
concentrations in the individual MCBs were substan-
tially different (< 0.01% vs 4.3% for 3D7-V1 MCB and 
3D7-MBE-008, respectively), the 3D7-MBE-008 partici-
pants likely received a higher mean dose of erythrocytes 
infected with ring stage parasites. Alternatively, host 
factors may have played a factor. The participants in the 
3D7-V1 study were younger than those in the MBE-008 
study; however, analysis of data from previous studies has 
not found an association between age and  PMR48 [25].
In addition to the slower growth rate of the 3D7-V1, 
another limitation for the 3D7-V1 MCB is that the origi-
nal donor is Rh(D) positive, thus precluding Rh negative 
females from enrolling in studies using this isolate due to 
the risk of red cell allo-immunization. As a consequence 
of this and the associated slower PMR, it is likely that the 
3D7-V1 MCB will be less suitable for use in further IBSM 
studies.
The adverse events reported for both studies are in 
keeping with previous IBSM studies [9–11, 28, 29]. The 
asymptomatic raised liver enzymes, with no associated 
significant rise in bilirubin, have been reported in previ-
ous IBSM studies [30, 31], sporozoite VIS [32] and in nat-
urally occurring malaria [30, 33]. Similarly, the reduction 
in white cell counts, especially lymphopenia and neutro-
penia have previously been reported in IBSM VIS, sporo-
zoite VIS and clinical malaria [12, 16, 34–36].
Both MCBs had similar parasite clearance profiles, with 
no recrudescence, further confirming that both MCBs 
are safe to use in malaria VIS. With the development of 
the biomanufactured MCB, there are now two further 
P. falciparum 3D7 MCBs that can be used in IBSM VIS. 
These are in addition to previously developed MCBs of 
non-falciparum species including Plasmodium vivax and 
Plasmodium malariae [11, 37, 38]. The development of 
these MCBs in falciparum and non-falciparum species 
may in future also enable IBSM VIS to be conducted in 
malaria endemic populations, to gain further under-
standing of host-immune response and to evaluate anti-
malarial drug efficacy in participants who are regularly 
exposed to natural malaria.
A limitation of this study was that the MCBs were 
each evaluated in only two participants. There is 
a need to, therefore, be cautious in comparing the 
parasite growth rates of the new MCBs against the 
established 3D7-V2 MCB, especially as there is vari-
ability within the observed growth rates and individ-
ual growth parameters within the 3D7-V2 MCB [25]. 
However, when comparing the growth rates of both 
3D7-MBE-008 and 3D7-V2, the individual parameters 
are similar (Additional file 1: Table S2).
Conclusion
A newly developed P. falciparum new MCB which is safe 
to use in healthy, malaria-naive participants is reported. 
The growth characteristics of the bioreactor-expanded P. 
falciparum 3D7-MBE-008 MCB have been demonstrated 
and are comparable to the existing 3D7 MCB, hence this 
new bank is suitable for use in future studies.
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